Gallium-68/Copper-64-FAPI-XT117 - Sinotau pharmaceuticals
Alternative Names: 68Ga/64Cu-FAPI-XT117Latest Information Update: 13 Oct 2025
At a glance
- Originator Sinotau Pharmaceuticals
 - Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
 - Mechanism of Action Positron-emission tomography enhancers
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- No development reported Solid tumours
 
Most Recent Events
- 13 Oct 2025 No development reported - Phase-I for Solid tumours (Diagnosis) in China (IV)
 - 18 Dec 2023 Sinotau Pharmaceutical completes a phase I trial in Solid tumours (Diagnosis) in China (IV) (NCT05930457)
 - 18 Dec 2023 Sinotau Pharmaceutical completes a phase I trials in Solid tumours (Diagnosis) in China (IV) (NCT05814835)